Please call your physician’s office before coming in for your appointment if you have symptoms of a cough, fever, or difficulty breathing; traveled to Europe or China or other areas impacted by the coronavirus (COVID-19) within the past 14 days; been in close contact with someone who has traveled outside the U.S. to one of the impacted countries; or may have been exposed to the coronavirus. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Our new office hours are: Monday through Friday 8:30 a.m. to 4:00 p.m, if you have an appointment scheduled for after hours, our office will be contacting you directly to reschedule. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE
Getting a diagnosis of cancer is the most challenging thing any patient and family will have to go through. My job is to provide the most comprehensive options for patients, with state-of-the-art care and compassion.
Work and Credentials:
Primary Location
Position
Medical Oncologist
Board Certification
Medical Oncology and Internal Medicine
Fellowship
Johns Hopkins Hospital, Medical Oncology
Internship
Hospital of the University of Pennsylvania
Residency
Hospital of the University of Pennsylvania
Medical School
New York University School of Medicine
College
Harvard University
Dr. Alex Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences.
As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology.
Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.
Physician Publications
October 1, 2019
A review of canakinumab and its therapeutic potential for non-small cell lung cancer.
Read MoreAugust 1, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Read MoreMore Publications by Alex Spira, MD, PhD, FACP
September 25, 2018
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
Read MoreMarch 9, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Read MoreSeptember 14, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
Read MoreJune 3, 2013
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.
Read MoreFebruary 1, 2013
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
Read MoreJanuary 2, 2013
Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue Sarcoma
Read MoreJune 1, 2012
Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancer
Read MoreApril 16, 2012
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Read MoreJanuary 1, 2012
Clinical trial design in the age of molecular profiling.
Read MoreSeptember 8, 2011
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Read MoreJune 1, 2011
Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients
Read MoreJune 1, 2011
Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).
Read MoreJune 1, 2011
Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
Read MoreDecember 4, 2010
Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.
Read MoreDecember 1, 2010
Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.
Read MoreDecember 3, 2009
Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and nonmyeloma bone marrow cell populations.
Read MoreDecember 1, 2009
Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Read MoreJanuary 22, 2004
Multidisciplinary Management of Lung Cancer
Read MoreJanuary 1, 2002
The use of Chemotherapy in Soft Tissue Sarcomas
Read MoreClinical Trials (63)
Clinical Trial APG-115-US-002
Clinical Trial KL26401
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies
Clinical Trial 19043
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)
Clinical Trial 19082
A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)
Clinical Trial TPX-005-001
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Clinical Trial PSB205
A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/ Refractory Solid Tumors
All Clinical Trials for Alex Spira, MD, PhD, FACP
Clinical Trial APG-115-US-002
Clinical Trial KL26401
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies
Clinical Trial 19043
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)
Clinical Trial 19082
A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)
Clinical Trial TPX-005-001
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Locations:
ClinicalTrials.gov ID:
NCT03093116
ClinicalTrials.gov Link:
Clinical Trial PSB205
A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/ Refractory Solid Tumors
Clinical Trial PLX124-01
A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Advanced Malignancies
Clinical Trial RMC-4630-02
A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors with Specific Genomic Aberrations
Clinical Trial ASTX295-01
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors
Clinical Trial 849-001
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Clinical Trial 19081
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1)
Clinical Trial KL166-I-01
A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies
Clinical Trial 14059
Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Locations:
ClinicalTrials.gov ID:
NCT3379428
Clinical Trial 101-18101
An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Clinical Trial CTMX-M-072-002
A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody™ Therapeutic CX 072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (PROCLAIM-CX-072)
Clinical Trial 18214
A PHASE 1/2 STUDY OF GALINPEPIMUT-S IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH SELECTED ADVANCED CANCERS (SLS17-201/MK3475-770)
Clinical Trial LOXO-RET-18037
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)
Clinical Trial 19024
Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (20170543)
Locations:
ClinicalTrials.gov ID:
NCT03600883
ClinicalTrials.gov Link:
Clinical Trial GO-005
A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors
Clinical Trial M14-239
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Clinical Trial C2321001
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Clinical Trial 18129
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Clinical Trial 1951-CL-0101
A Phase 1 Study of ASP1951 in Subjects with Advanced Solid Tumors
Clinical Trial LOXO-RET-17001
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001
Clinical Trial CP-MGC018-01
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors
Clinical Trial 18233
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Gastrointestinal Malignancies
Clinical Trial AO-176-101
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Clinical Trial ARYS-002
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
Clinical Trial 18-234
(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Clinical Trial GO-004
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors
Clinical Trial KL 166-I-01
A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies
Clinical Trial AMXT1501-101A
PHASE I DOSE-FINDING, SAFETY STUDY OF ORAL AMXT 1501 DICAPRATE AND DIFLUOROMETHYLORNITHINE (DFMO) IN PATIENTS WITH ADVANCED SOLID TUMORS
Clinical Trial Bayer 18594
An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas
Clinical Trial Janssen 61186372EDI10051
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Clinical Trial 17143
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)
Clinical Trial 18033
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Locations:
ClinicalTrials.gov ID:
NCT03606174
ClinicalTrials.gov Link:
Clinical Trial GO-003
An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients with Advanced Cancer
Locations:
Clinical Trial ADCT-402-201
Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical Trial 17-167
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)
ClinicalTrials.gov ID:
NCT03447769
ClinicalTrials.gov Link:
Clinical Trial 1948-CL-0101
A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors
Clinical Trial TROV-052
A Phase 1b/2 Study of PCM-075 in Combination with either Low-Dose Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia (AML)
Clinical Trial CTMX-M-2029-001
A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)
Clinical Trial 18-057
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Clinical Trial 18-020
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Clinical Trial Astex ASTX029
Study of ASTX029 in Subjects With Advanced Solid Tumors
Clinical Trial 17-140
A Phase III, Double-Blinded, Multi-center, Randomized Study Evaluating The Efficacy and Safety of Neo-adjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Locations:
ClinicalTrials.gov ID:
NCT03456063
ClinicalTrials.gov Link:
Clinical Trial STRO-001-BCM1
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Clinical Trial DS1062-A-J101
First-in-human Study of DS-1062a for Advanced Solid Tumors
Clinical Trial BGB-A317
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors.
Clinical Trial Tesaro 4020-01-001
A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Trial R3767-ONC-1613
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Clinical Trial CTMX-M-2009-001
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors(PROCLAIM-CX-2009)
Clinical Trial 8374-CL-0101
A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors
Clinical Trial M16-074
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects with Locally Advanced or Metastatic Solid Tumors
Clinical Trial M14-237
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors
Clinical Trial STARTRK-2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of patients with locally advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements.
Clinical Trial CINC280A2201
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease.
Locations:
ClinicalTrials.gov ID:
NCT02414139
ClinicalTrials.gov Link:
Clinical Trial 15-239
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications – EMD Serono EMR 200647-001.
Clinical Trial Mirati 516-001
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Locations:
ClinicalTrials.gov ID:
NCT02219711
ClinicalTrials.gov Link:
Clinical Trial MRTX-500
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Clinical Trial AbbVie M15-862
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects with Advanced Solid Tumors
Clinical Trial AbbVie M15-891
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody, in Subjects with Advanced Solid Tumors
Clinical Trial 16-006
A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022)
ClinicalTrials.gov ID:
NCT02864992
ClinicalTrials.gov Link:
